Search results for: W. Timothy Garvey

Items from 1 to 20 out of 70 results

article

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

Emily R. Hankosky, Hui Wang, Lisa M. Neff, Hong Kan, more

Diabetes, Obesity and Metabolism > 25 > 12 > 3748 - 3756

Aim We assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT‐1 trial. Materials and Methods In this post hoc analysis of SURMOUNT‐1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10‐year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or...

article

Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity

Lua Wilkinson, Thomas Holst‐Hansen, Peter N. Laursen, Anders R. Rinnov, more

Obesity > 31 > 9 > 2249 - 2259

Objective In the Semaglutide Treatment Effect in People with obesity (STEP) trials, once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body weight and improved cardiometabolic parameters in adults with obesity (or overweight with weight‐related comorbidities). Effects on the risk of developing type 2 diabetes (T2D) require investigation. Methods STEP 1 (68 weeks) and...

article

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Sean Wharton, Rachel L. Batterham, Meena Bhatta, Silvio Buscemi, more

Obesity > 31 > 3 > 703 - 715

Objective This study evaluated the effect of once‐weekly semaglutide 2.4 mg on 2‐year control of eating. Methods In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19‐item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled...

article

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Mikhail N. Kosiborod, Meena Bhatta, Melanie Davies, John E. Deanfield, more

Diabetes, Obesity and Metabolism > 25 > 2 > 468 - 478

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP 1 and 4 trials. Materials and Methods STEP 1 and 4 were phase III, 68‐week, placebo‐controlled trials of once‐weekly semaglutide 2.4 mg combined with lifestyle intervention; STEP 4 had a 20‐week semaglutide run‐in and 48‐week randomized...

article

Examining the evidence for weight management in individuals with type 2 diabetes

W. Timothy Garvey, Guillermo E. Umpierrez, Julia P. Dunn, Anita Y. M. Kwan, more

Diabetes, Obesity and Metabolism > 24 > 8 > 1411 - 1422

The obesity epidemic has been linked to the worsening diabetes epidemic. Despite this, weight reduction for individuals with obesity is seen as a secondary, or even tertiary, consideration in the treatment of type 2 diabetes (T2D). The aim of this review is to examine the benefits of weight management in individuals with T2D. A literature review of current available published data on the benefits...

article

Associations between cardiometabolic disease severity, social determinants of health (SDoH), and poor COVID‐19 outcomes

Carrie R. Howell, Li Zhang, Nengjun Yi, Tapan Mehta, more

Obesity > 30 > 7 > 1483 - 1494

Objective This study aimed to determine the ability of retrospective cardiometabolic disease staging (CMDS) and social determinants of health (SDoH) to predict COVID‐19 outcomes. Methods Individual and neighborhood SDoH and CMDS clinical parameters (BMI, glucose, blood pressure, high‐density lipoprotein, triglycerides), collected up to 3 years prior to a positive COVID‐19 test, were extracted from...

article

Long‐term health benefits of intensive lifestyle intervention in the Look AHEAD study

W. Timothy Garvey

Obesity > 29 > 8 > 1242 - 1243

article

Genetic landscape of Gullah African Americans

Kip D. Zimmerman, Theodore G. Schurr, Wei‐Min Chen, Uma Nayak, more

American Journal of Physical Anthropology > 175 > 4 > 905 - 919

Objectives Gullah African Americans are descendants of formerly enslaved Africans living in the Sea Islands along the coast of the southeastern U.S., from North Carolina to Florida. Their relatively high numbers and geographic isolation were conducive to the development and preservation of a unique culture that retains deep African features. Although historical evidence supports a West‐Central African...

article

Diagnosing Obesity as a First Step to Weight Loss: An Observational Study

Elizabeth L. Ciemins, Vaishali Joshi, John K. Cuddeback, Robert F. Kushner, more

Obesity > 28 > 12 > 2305 - 2309

Objective This study aimed to explore the relationship between an obesity diagnosis and weight loss as a percentage of total body weight loss over 9 to 15 months, using electronic health record data. Methods An observational study of 688,878 adult patients at 15 health systems with BMI ≥ 30 kg/m² examined the relationship between weight loss and documentation of obesity diagnosis. Multivariable...

article

Response to “The Future of Obesity Diagnostic Coding”

W. Timothy Garvey, Jeffrey I. Mechanick

Obesity > 28 > 7 > 1169 - 1170

article

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Robert F. Kushner, Salvatore Calanna, Melanie Davies, Dror Dicker, more

Obesity > 28 > 6 > 1050 - 1061

Objective The obesity epidemic is a public health concern, warranting further research into pharmacological treatments for weight management (WM) as an adjunct to lifestyle interventions. The Semaglutide Treatment Effect in People with obesity (STEP) program aims to investigate the effect of semaglutide versus placebo on weight loss, safety, and tolerability in adults with obesity or overweight....

article

Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists

Jeffrey I. Mechanick, Caroline Apovian, Stacy Brethauer, W. Timothy Garvey, more

Obesity > 28 > 4 > O1 - O58

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), Obesity Medicine Association (OMA), and American Society of Anesthesiologists (ASA) Boards of Directors in adherence with the AACE 2017 protocol for...

article

Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity

W. Timothy Garvey, Jeffrey I. Mechanick

Obesity > 28 > 3 > 484 - 492

Objective Obesity is responsible for a huge burden of suffering and social costs, and yet many patients lack access to evidence‐based therapies. The diagnostic term “obesity” and inadequate International Classification of Diseases(ICD) codes contribute to suboptimal efforts to prevent and treat obesity as a chronic disease. The goal of this review is to develop a medically actionable classification...

article

Core Principles, Treatment Standards, and Provider Competencies for the Care of Patients with Obesity

W. Timothy Garvey

Obesity > 27 > 7 > 1045 - 1047

article

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

W. Timothy Garvey, Luc Van Gaal, Lawrence A. Leiter, Ujjwala Vijapurkar, more

Metabolism > 2018 > 85 > C > 32-37

Type 2 diabetes and obesity are pro-inflammatory states associated with increased risk of cardiovascular disease. Canagliflozin, an SGLT2 inhibitor, demonstrated superiority in lowering HbA1c versus glimepiride with less hypoglycemia and greater weight reduction via loss of fat mass in a 52-week trial of type 2 diabetes patients. This post hoc, exploratory analysis assessed the effects of canagliflozin...

article

Improved systemic metabolism and adipocyte biology in miR-150 knockout mice

Minsung Kang, Xiaobing Liu, Yuchang Fu, W. Timothy Garvey

Metabolism > 2018 > 83 > C > 139-148

Short non-coding micro-RNAs (miRNAs) are post-transcriptional factors that directly regulate protein expression by degrading or inhibiting target mRNAs; however, the role of miRNAs in obesity and cardiometabolic disease remains unclarified. Based on our earlier study demonstrating that miR-150 influences lipid metabolism, we have studied effects of miR-150 on systemic metabolism and adipocyte biology...

article

Leptin, An Adipokine With Central Importance in the Global Obesity Problem

Jeffrey I. Mechanick, Shan Zhao, W. Timothy Garvey

Global Heart > 2018 > 13 > 2 > 113-127

Leptin has central importance in the global obesity and cardiovascular disease problem. Leptin is principally secreted by adipocytes and acts in the hypothalamus to suppress appetite and food intake, increase energy expenditure, and regulate body weight. Based on clinical translation of specific and networked actions, leptin affects the cardiovascular system and may be a marker and driver of cardiometabolic...

article

Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12‐Week Treatment: A Randomized Substudy

Candida J. Rebello, Elena V. Nikonova, Sharon Zhou, Louis J. Aronne, more

Obesity > 26 > 2 > 332 - 339

Objective This study evaluated the effect of lorcaserin 10 mg twice daily (LOR BID), or with phentermine 15 mg once daily (LOR BID + PHEN QD) and 15 mg twice daily (LOR BID + PHEN BID), in conjunction with energy restriction on food cravings. Methods Two hundred and thirty‐five patients without diabetes but with obesity or overweight and ≥ 1 comorbidity received LOR BID, LOR BID + PHEN QD, or LOR...

article

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Lauren Holland-Carter, Peter W. Tuerk, Thomas A. Wadden, Ken N. Fujioka, more

Journal of Diabetes and its Complications > 2017 > 31 > 5 > 891-897

Type 2 diabetes mellitus (T2DM) can substantially decrease quality of life (QOL). This study examined the effects on QOL-relevant psychosocial measures of a widely available commercial weight loss program enhanced for individuals with T2DM.A year-long multi-site randomized clinical trial compared the Weight Watchers (WW) approach, supplemented with phone and email counseling with a certified diabetes...

article

Coadministration of lorcaserin and phentermine for weight management: A 12‐week, randomized, pilot safety study

Steven R. Smith, W. Timothy Garvey, Frank L. Greenway, Sharon Zhou, more

Obesity > 25 > 5 > 857 - 865

Objective To assess the short‐term tolerability of lorcaserin alone or with two dose regimens of phentermine. Methods This was a 12‐week, randomized, double‐blind, pilot safety study of N = 238 nondiabetic patients with obesity or overweight with ≥1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 mg twice...

Publication date

Last 3 years (6)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Content availability

Available (69)
None (1)

Publication type

article (68)
book (2)

Keywords

Data set

Elsevier (42)
Wiley (21)
Springer (6)
ACS (1)

Journal

Obesity (15)
Atherosclerosis (7)
Metabolism (5)
Journal of Diabetes and Its Complications (4)
Diabetes, Obesity and Metabolism (3)
Nutrition (3)
Clinical Cornerstone (2)
Diabetes Research and Clinical Practice (2)
Endocrine (2)
Journal of the American College of Cardiology (2)
The American Journal of Medicine (2)
American Journal of Physical Anthropology (1)
Artery Research (1)
Biochemical and Biophysical Research Communications (1)
Biochemistry (1)
Blood Cells, Molecules and Diseases (1)
Bone (1)
Current Obesity Reports (1)
Data in Brief (1)
Experimental Physiology (1)
FEBS Letters (1)
Global Heart (1)
Health Economics Review (1)
Journal of Chromatography B: Biomedical Sciences and Applications (1)
Journal of Diabetes and its Complications (1)
Journal of General Internal Medicine (1)
Journal of Psychiatric Research (1)
Journal of the American Society of Hypertension (1)
Neurobiology of Learning and Memory (1)
Psychoneuroendocrinology (1)
Surgery for Obesity and Related Diseases (1)
The American Journal of Human Genetics (1)
more

INFONA - science communication portal

Search results for: W. Timothy Garvey

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Examining the evidence for weight management in individuals with type 2 diabetes

Associations between cardiometabolic disease severity, social determinants of health (SDoH), and poor COVID‐19 outcomes

Long‐term health benefits of intensive lifestyle intervention in the Look AHEAD study

Genetic landscape of Gullah African Americans

Diagnosing Obesity as a First Step to Weight Loss: An Observational Study

Response to “The Future of Obesity Diagnostic Coding”

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity

Core Principles, Treatment Standards, and Provider Competencies for the Care of Patients with Obesity

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Improved systemic metabolism and adipocyte biology in miR-150 knockout mice

Leptin, An Adipokine With Central Importance in the Global Obesity Problem

Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12‐Week Treatment: A Randomized Substudy

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Coadministration of lorcaserin and phentermine for weight management: A 12‐week, randomized, pilot safety study

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: W. Timothy Garvey

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options